Lower Efficacy Rate Of J&J’s COVID-19 Vaccine Presents ‘Messaging Challenge’
While vaccine has efficacy rate of 74% in the US, it completely prevented hospitalizations and deaths, which Fauci says is the most important result from a public health perspective. Vaccine findings cannot be compared given emergence of variants since Moderna and Pfizer conducted their studies, Janssen global head of R&D says.
You may also be interested in...
Pandemic Perspectives: Paul Offit On COVID-19 Vaccine Worries, Country’s Worst Biological Disaster, And What Lies Ahead
The prominent virologist and vaccine expert talks to the Pink Sheet about how COVID-19 vaccines could change future research, the ‘Rosetta Stone’ of the polio vaccine tragedy, and the 26-year effort to create a rotavirus vaccine.
US FDA’s Peter Marks notes timeframe for sponsors to seek licensure at press call announcing emergency use authorization of J&J’s vaccine; Acting Commissioner Woodcock says effectiveness comparisons cannot be made between the three authorized vaccines since they have not been tested head-to-head.
Efficacy against moderate to severe/critical COVID-19 was 66%-67%, well above the FDA’s stated 50% efficacy threshold for an EUA but far short of the 94%+ efficacy rates posted by the Pfizer and Moderna vaccines against symptomatic disease; agency says efficacy against specific variants cannot be evaluated at this time because sequencing data are incomplete.